NASDAQ: ZURAZura Bio Ltd Stock
$1.39-0.02 (-1.42%)
Updated Apr 29, 2025
ZURA Price
$1.39
Fair Value Price
$2.35
Market Cap
$95.04M
52 Week Low
$0.97
52 Week High
$6.35
P/E
-2.32x
P/B
0.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$52.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$28M
Beta
0.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZURA Overview
JATT Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the life sciences sector. JATT Acquisition was incorporated in 2021 and is based in Grand Cayman, Cayman Islands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZURA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ZURA
Ranked#385 of 462
Ranked#385 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important ZURA news, forecast changes, insider trades & much more!
ZURA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZURA ($1.39) is undervalued by 40.88% relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ZURA ($1.39) is significantly undervalued by 40.88% relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ZURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ZURA due diligence checks available for Premium users.
Valuation
ZURA fair value
Fair Value of ZURA stock based on Discounted Cash Flow (DCF)
Price
$1.39
Fair Value
$2.35
Undervalued by
40.88%
ZURA ($1.39) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ZURA ($1.39) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ZURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ZURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.32x
Industry
-158.75x
Market
29.19x
ZURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
4.37x
ZURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.6M
Profit Margin
0%
ZURA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$179.5M
Liabilities
$19.5M
Debt to equity
0.13
ZURA's short-term assets ($178.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZURA's short-term assets ($178.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
-$45.0k
Financing
-$854.0k
ZURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZURA vs Biotech Stocks
Zura Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.